A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient Treated with Guselkumab.
PASI
Psoriasis
anti-IL-23
guselkumab
hepatitis C
hepatitis C reactivation
Journal
Current drug safety
ISSN: 2212-3911
Titre abrégé: Curr Drug Saf
Pays: United Arab Emirates
ID NLM: 101270895
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
06
2021
revised:
25
10
2021
accepted:
22
12
2021
pubmed:
9
3
2022
medline:
30
7
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
Psoriasis is a chronic inflammatory skin disease requiring long-term treatment. However, there are approximately 71 million individuals with chronic HCV infection worldwide. In psoriatic patients affected by chronic HCV infection, conventional systemic drugs may be frequently contraindicated, while data on biologics use are limited. The case of a 48-year-old Caucasian man suffering from a severe form of plaque psoriasis and affected by a chronic-HCV-infection treated with guselkumab has been reported. Despite a huge improvement of the skin lesions (PASI reduced from 18 to 2), guselkumab was discontinued due to an HCV-infection reactivation after 3 months of treatment. To the best of our knowledge, this is the first case report of the use of guselkumab in an HCV psoriatic patient. Further studies are needed to evaluate the safety of guselkumab in chronic HCV patients.
Identifiants
pubmed: 35255793
pii: CDS-EPUB-121399
doi: 10.2174/1574886317666220307112926
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
guselkumab
089658A12D
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-392Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.